Michael Mollerus

Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000 shares of common stock of Melinta Therapeutics, Inc., including…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 4,057,500 shares of common stock of Calyxt, Inc., including 457,500…

Davis Polk is advising IHS Markit on its $1.855 billion acquisition of Ipreo from private equity funds managed by Blackstone and the Goldman Sachs Merchant Banking Division. The acquisition…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of $500 million aggregate principal amount of its 5.375% senior notes due 2027 and a concurrent amendment…

Davis Polk advised the joint book-running managers in connection with the offering by Canadian Pacific Railway Company of $500 million aggregate principal amount of 4.000% notes due…

Davis Polk advised the joint book-running managers and representatives of the underwriters in an SEC-registered offering by General Dynamics Corporation of $500 million aggregate…

Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…

Davis Polk advised Goosehead Insurance, Inc. on its $98.095 million initial public offering of 9,809,500 shares of Class A common stock, which includes the full exercise of the underwriters…

Davis Polk is advising Emerson Electric Co. on its $810 million acquisition of the Tools and Test Equipment business of Textron. The transaction, which is expected to close within the next…

Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…